

V, R., Male AGE 60


02/01/01 Inoperable Lung Cancer Determined by biopsy

02/15/01 Patient presented to us with inoperable squamous cell carcinoma of the left lung. The patient is unable to walk unassisted, and was helped into our office by his son. His vocal chords suffered damage in the bronchoscopy, and he is too short of breath to speak well. His lips have a blue tinge and he is obviously suffering from oxygen deprivation. The patient presents also with a quarter size squamous cell tumor on his right forearm, which has been repeatedly removed and re-grown over the past 9 years. He is suffering from chronic hypertension and is on blood pressure medication. Patient is depressed and fairly hopeless. Due to financial stress on the patient, he is unable to obtain recommended lab work.

02/15/01 Ten days following the start of the LifeOne Formula, the large squamous cell tumor on his right arm fell off, with no visible scar or recurrence. The patient's strength has returned rapidly and he was able to come to the follow up visit on his own. He appears less fatigued and is breathing easier. Patient began slowly getting back into every day living and started to get back into doing his own yard work. The patient is increasingly energetic and very animated. Patient began acting as our office chauffeur for our out of town visitors. Patient has worked up to two 30-minute walks daily and has resumed helping his elderly Mother.

08/13/01 Patient began experiencing neck and shoulder pain.

09/28/01 Mr. Vrana deceased due to heart failure.




Life Expectancy Reference:

PMID: 11742706 [PubMed-indexed for MEDLINE]

Cancer 2001 Nov 15;92(10):2639-47


Outcome of patients with a performance status of 2 in Easter Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma.

Sweeny CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson, DH
Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center,
Indianapolis, Indiana, USA




Normal Range 440-1600

Note that his rapid increase in CD4 declines when the LifeOne Formula dosage is decreased, and resumes when the normal dosage is resumed.



Normal Range 70-640

Note that his rapid increase in CD8 declines when the LifeOne Formula dosage is decreased, and resumes when the normal dosage is resumed.



Normal Range 110-660

Note that his rapid increase in CD19 declines when the LifeOne Formula dosage is decreased, and resumes when the normal dosage is resumed.

These graphs represent the formulas measurable, beneficial effects on the various cell types in the immune system.